| Date | Title | Description |
| 30.03.2026 | Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 30, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of... |
| 24.03.2026 | KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF | Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximately RMB1478.78 million, representing a year-on-year increase.
R&D Expenses was approximately RMB1319.68 million.
Loss for the period was RMB381... |
| 23.03.2026 | Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 23, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery and development of novel antibody the... |
| 19.03.2026 | Harbour BioMed Appoints Dr. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 19, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody thera... |
| 09.03.2026 | Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis | CHENGDU, China, March 9, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) and Harbour BioMed (HKEX: 02142) today announced that the National Medical Produ... |
| 09.03.2026 | Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 9, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology an... |
| 04.02.2026 | Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 4, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therape... |
| 29.01.2026 | AstraZeneca invests $15bn in China through 2030 | AstraZeneca invests $15bn in China through 2030
Thu, Jan 29, 2026 11:24 CET Report this content
29 January 2026
AstraZeneca plans to invest $15 billion in China through 2030 to pioneer the next-generation of innovative medicines
Landmark in... |
| 19.01.2026 | Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 19, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology an... |
| 29.12.2025 | Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology an... |
| 17.12.2025 | Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies | SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, Dec. 17, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology an... |
| 24.11.2025 | Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 24, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of ... |
| 07.11.2025 | Harbour BioMed and Evinova China Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 7, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of n... |
| 28.10.2025 | Harbour BioMed Launches First Fully Human Generative AI HCAb Model to Accelerate Next-Generation Biologics Discovery | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 28, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and ... |
| 27.08.2025 | Harbour BioMed Reports 2025 Interim Results | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of ... |
| 25.08.2025 | Harbour BioMed Appoints Yajie Li as Chief Medical Officer | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therap... |
| 18.08.2025 | KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS | Revenue reached approximately RMB950.4 million, with total commercial sales RMB309.8million, representing a significant increase in proportion
Research and development expenses was approximately RMB611.5 million
Loss for the period was RMB1... |
| 30.07.2025 | Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025 | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 30, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and ... |
| 28.07.2025 | Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 28, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therap... |
| 25.07.2025 | Hong Kong biotech enters its second act with a licensing supercycle | As summer arrives, the rally in Hong Kong-listed biotech stocks is still going strong.
In the first half of the year, companies like Harbour BioMed (HBM), Jacobio Pharmaceuticals, and 3SBio saw their share prices more than triple, with seve... |
| 23.07.2025 | HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma | Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma, with an initial data readout expected in mid-2026
HBM9378/WIN378 has the potential to be the first-to-market long-acting anti-TS... |
| 23.07.2025 | Kelun-Biotech's Partner Windward Bio Announces Initiation of a Global Phase 2 Asthma Trial of SKB378/WIN378 | CHENGDU, China, July 23, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", HKEX: 6990) today announced that its partner, Windward Bio AG ("Windward Bio") ... |
| 23.06.2025 | Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 23, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology an... |
| 16.06.2025 | China National Intellectual Property Administration Affirms Validity of Harbour BioMed's Patent; Infringement Lawsuit Moves Forward | CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI, June 16, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on i... |
| 10.04.2025 | Harbour BioMed Appoints Youchen Chen as Chief Financial Officer | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , April 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on im... |
| 31.03.2025 | Harbour BioMed Reports Full Year 2024 Financial Results | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of... |
| 25.03.2025 | Tariff Flexibility: A Double-Edged Sword for Markets | In the world of finance, uncertainty is like a storm cloud. It looms, casting shadows over markets and making investors uneasy. Recently, U.S. President Donald Trump hinted at “flexibility” regarding tariffs. This word, while seemingly beni... |
| 24.03.2025 | CNBC Daily Open: Tariff flexibility sounds good, but also signals uncertainty | “Flexibility” connotes openness to change. U.S. President Donald Trump expressed Friday the possibility of being flexible with tariffs, which may have helped stocks tick up, pushing the three key U.S. benchmarks into the green for the week.... |
| 21.03.2025 | AstraZeneca's Bold Leap into Beijing: A New Era for Biopharmaceutical Innovation | AstraZeneca is making waves in the biopharmaceutical ocean. The company recently announced a staggering $2.5 billion investment in Beijing. This move is not just a financial commitment; it’s a strategic pivot that could reshape the landscap... |
| 21.03.2025 | AstraZeneca to invest $2.5 billion in Beijing hub as it looks beyond Chinese tax probe | British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in Beijing, China.
Under the deal, AstraZeneca will enter research and development collaborations with biotec... |
| 21.03.2025 | Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies | SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, March 21, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeut... |
| 21.03.2025 | AZN invests $2.5bn in Beijing R&D & manufacturing | AZN invests $2.5bn in Beijing R&D & manufacturing
Fri, Mar 21, 2025 12:37 CET Report this content
21 March 2025
AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beiji... |
| 12.03.2025 | Harbour BioMed Launches Élancé Therapeutics to Advance Next-Generation Obesity Therapies | - Élancé Therapeutics aims to improve current obesity treatment, specifically to increase overall body weight loss and fat mass loss, but preserve and even increase muscle and lean mass
- Élancé Therapeutics will leverage HCAb-based bispeci... |
| 11.03.2025 | Navigating Market Currents: A Strategic Shift in Investments | In the ever-changing landscape of the stock market, strategic decisions can feel like navigating a ship through turbulent waters. Investors must adjust their sails to catch the right winds. Recently, two notable trades have emerged, showcas... |
| 11.03.2025 | Harbour BioMed Appoints Dr. Ian Y. Liu as Global Head of Legal | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 11, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeut... |
| 11.03.2025 | Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 11, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeut... |
| 26.02.2025 | HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine Therapies | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Feb. 26, 2025 /PRNewswire/ -- HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142), announced a strategic collaboration a... |
| 20.02.2025 | The Future of Antibody Therapy: A New Era of Collaboration and Innovation | In the fast-paced world of biopharmaceuticals, collaboration is the name of the game. Harbour BioMed and Insilico Medicine are leading the charge. Their recent partnership marks a significant leap in antibody discovery and development. This... |
| 20.02.2025 | Harbour BioMed and Insilico Medicine Achieve Strategic Collaboration to Advance AI-Driven Antibody Discovery and Development | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 20, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of ... |
| 14.02.2025 | Harbour BioMed Announces Business Progress and Update | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 14, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of... |
| 05.02.2025 | Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 5, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of n... |
| 14.01.2025 | Windward Bio: Charting New Waters in Immunology with $200 Million Series A Financing | In the vast ocean of biopharmaceutical innovation, Windward Bio has set sail with a robust $200 million Series A financing. This private, clinical-stage company aims to navigate the turbulent waters of immunological diseases, focusing on se... |
| 13.01.2025 | Windward Bio launches with $200 million Series A financing round |
Windward Bio’s lead candidate, WIN378, which has been in-licensed from Kelun-Biotech and Harbour BioMed, is a potential best-in-class, long-acting monoclonal antibody targeting the ligand of thymic stromal lymphopoietin (TSLP) that has the... |
| 11.01.2025 | A New Dawn in Immunotherapy: Harbour BioMed and Kelun-Biotech's Strategic Move with Windward Bio | In the fast-paced world of biopharmaceuticals, partnerships can be the lifeblood of innovation. The recent collaboration between Harbour BioMed, Kelun-Biotech, and Windward Bio marks a significant milestone in the development of immunologic... |
| 10.01.2025 | Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of ... |
| 15.11.2024 | Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 15, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercializati... |
| 08.11.2024 | Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 8, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercializatio... |
| 01.11.2024 | HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update | HanAll records revenue of 36.8 billion KRW in the third quarter, with an operating profit of 430 million KRW.
Results for the Phase 1 study in healthy subjects for HL192 (ATH-399A), a novel compound targeting Parkinson's Disease, are expect... |
| 10.10.2024 | Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Oct. 10, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercializati... |
| 19.09.2024 | Promising Advances in Cancer and Heart Failure Treatments: A Look at Harbour BioMed and AnaCardio | In the world of biopharmaceuticals, innovation is the lifeblood. Two companies, Harbour BioMed and AnaCardio, are making waves with their latest clinical trials. Both are pushing the boundaries of treatment for serious health conditions: ad... |
| 14.09.2024 | Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024 | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Sept. 14, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercializat... |
| 29.08.2024 | Harbour BioMed and Keymed Biosciences: Navigating the Biopharmaceutical Landscape in 2024 | In the ever-evolving world of biopharmaceuticals, two companies stand out: Harbour BioMed and Keymed Biosciences. Both are charting ambitious paths through the complex terrain of drug development, showcasing resilience and innovation. Their... |
| 28.08.2024 | Harbour BioMed Announces 2024 Interim Results | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development,... |
| 28.08.2024 | Harbour BioMed Announces 2024 Interim Results | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development,... |
| 28.07.2024 | New Frontiers in Cancer Treatment: Breakthroughs from Harbour BioMed and Astellas Pharma | In the relentless battle against cancer, innovation is the sword that cuts through despair. Two recent announcements from Harbour BioMed and Astellas Pharma illuminate the path forward, showcasing novel therapies that could reshape treatmen... |
| 28.07.2024 | HanAll Biopharma: Navigating Challenges and Opportunities in Q2 2024 | HanAll Biopharma, a global player in the biopharmaceutical arena, recently unveiled its financial results for the second quarter of 2024. The numbers tell a story of resilience amid challenges. Total revenue reached 31.6 billion KRW, a slig... |
| 26.07.2024 | HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update | HanAll reports strong financial performance with second quarter total revenue of 31.6 billion KRW, driven by the strong sales from the key products.
HanAll expands collaboration with Turn Biotechnologies through an exclusive licensing agree... |
| 26.07.2024 | HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update | HanAll reports strong financial performance with second quarter total revenue of 31.6 billion KRW, driven by the strong sales from the key products.
HanAll expands collaboration with Turn Biotechnologies through an exclusive licensing agree... |
| 26.07.2024 | Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024 | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China , July 26, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercializat... |
| 25.07.2024 | Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024 | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China , July 25, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercializat... |
| 19.07.2024 | Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, July 19, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercializati... |
| 18.07.2024 | Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, July 18, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercializati... |
| 27.06.2024 | Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, June 27, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercializati... |
| 26.06.2024 | Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, June 26, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercializati... |
| 30.04.2024 | HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update | Delivered solid performance to start 2024, with record-breaking first quarter revenue of 34.1 billion KRW. Strong sales momentum continued from key products, funding investments in ongoing R&D programs.
Phase 3 VELOS-4 study of tanfaner... |
| 28.03.2024 | Harbour BioMed Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 28, 2024 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development ... |
| 28.03.2024 | Harbour BioMed Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 28, 2024 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development ... |
| 21.03.2024 | HanAll Biopharma Reports Full-Year 2023 Financial Results and Provides Business Update | Full-year 2023 net revenue reaches 135 billion KRW, driven by strong sales growth.
R&D momentum persisted with promising developments in anti-FcRn antibodies HL161ANS and batoclimab, positioning them as potentially best-in-class treatme... |
| 24.01.2024 | Harbour BioMed Announces IND Clearance for HBM9027 in the U.S. | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Jan. 24, 2024 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142) announced that the Company has been granted the clearance of Investigational New Drug (IND) from... |
| 19.01.2024 | Harbour BioMed Announces Positive Profit Alert | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Jan. 19, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercializati... |
| 28.08.2023 | Harbour BioMed Announces 2023 Interim Results | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development,... |
| 08.08.2023 | Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 8, 2023 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercializatio... |
| 13.07.2023 | Harbour BioMed Announces 2023 Interim Results Positive Profit Alert with the Enhancement of Value Driven by Innovation | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, July 13, 2023 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercializati... |
| 29.06.2023 | Harbour BioMed Announces Biologics License Application Acceptance of Batoclimab for Treatment of Generalized Myasthenia Gravis by NMPA | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, June 29, 2023 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercializati... |
| 05.06.2023 | Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020 | HBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally.
HBM1020 was generated from Harbour Mice® H2L2 transgenic mice platform.
HBM1020 has great potential to address huge unmet... |
| 06.03.2023 | Harbour BioMed Announces Positive Topline Results from Phase III Trial of Batoclimab for Treatment of Generalized Myasthenia Gravis | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 6, 2023 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercializati... |
| 26.01.2023 | HBM Alpha Therapeutics Raises Seed Round to Advance Next-Gen Therapies for Endocrine Disorders | CAMBRIDGE, Mass., Jan. 26, 2023 /PRNewswire/ -- HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142), announced that it completed seed financing to advance its leading programs,... |
| 26.01.2023 | HBM Alpha Therapeutics Raises Seed Funding | HBM Alpha Therapeutics, a Cambridge, MA-based biotechnology company incubated by Harbour BioMed (HKEX: 02142), raised a Seed funding round of undisclosed amount.
The company intends to use the funds to advance its leading programs, novel an... |
| 26.01.2023 | HBM Alpha Therapeutics Raises Seed Round to Advance Next-Gen Therapies for Endocrine Disorders | CAMBRIDGE, Mass., Jan. 26, 2023 /PRNewswire/ -- HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142), announced that it completed seed financing to advance its leading programs,... |
| 09.08.2022 | Harbour BioMed to Announce 2022 Interim Results on August 31, 2022 | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142) announced that it will report financial results for the first half year ended June 30, 2022, on W... |
| 19.10.2021 | Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase II Trial in Patients with Thyroid Eye Disease | CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Oct. 19, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, the clinical trial of its anti-FcRn antibody, batoclimab (HBM9161), has completed the... |
| 27.09.2021 | Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase III Trial in Patients with Generalized Myasthenia Gravis | CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 27, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, the clinical trial of its anti-FcRn antibody, batoclimab (HBM9161), has completed th... |
| 14.09.2021 | Harbour BioMed Announces NMPA Approval of Two IND Applications for Next-Generation Anti-CTLA-4 Antibody HBM4003 | |
| 14.09.2021 | Harbour BioMed : Announces NMPA Approval of Two IND Applications for Next-Generation Anti-CTLA-4 Antibody HBM4003 | CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 14, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that the China National Medical Products Administration (NMPA) has approved its Investigat... |
| 13.09.2021 | Harbour BioMed Announces Phase I Study Positive Results on Next-Generation Anti-CTLA-4 Antibody HBM4003 | CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 13, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced positive results from its phase I dose escalation clinical trial of HBM4003 in solid tumor... |
| 13.09.2021 | Harbour BioMed Announces Phase I Study Positive Results on Next-Generation Anti-CTLA-4 Antibody HBM4003 | |
| 01.09.2021 | Harbour BioMed Announces IND Approval for Phase II Trial of Anti-FcRn Batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy in China | CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 1, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administ... |
| 01.09.2021 | Harbour BioMed Announces IND Approval for Phase II Trial of Anti-FcRn Batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy in China | |
| 26.07.2021 | HBM Presents Phase I Data on Next-Generation Anti-CTLA-4 Antibody at ESMO Congress 2021 | CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, July 26, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced that the abstract detailing clinical data from its Australian phase I study of next-g... |
| 20.07.2021 | Harbour BioMed Appoints Yingying Chen, PhD, as Chief Financial Officer | CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, July 20, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX:02142) announced the appointment of Dr. Yingying Chen as Chief Financial Officer (CFO). Dr. Chen will be resp... |
| 06.07.2021 | Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis | Both batoclimab 340 mg and 680 mg treatment groups demonstrated rapid, substantial and persistent clinical improvement over placebo
Favorable safety and tolerability profile with no serious adverse events (SAEs) and no adverse events (AEs) ... |
| 17.06.2021 | Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC | CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 17, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced the dosing of the first patient of HBM4003 in patients with advanced non-small cell l... |
| 17.06.2021 | Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC | |
| 16.06.2021 | Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for Cancer Treatment | CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 15, 2021 /PRNewswire/ -- Harbour BioMed (HKEX: 02142) announced today it has entered into a multi-year, multifaceted research collaboration agreement with Dana-Farber Cance... |
| 11.05.2021 | Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody | |
| 11.05.2021 | Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody | CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 11, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced the dosing of the first patient in its part 2 of phase I (phase Ib/IIa) clinical study... |
| 21.03.2021 | Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China | |
| 27.01.2021 | Harbour BioMed's Batoclimab (HBM9161) Receives China CDE Breakthrough Therapy Designation for Treatment of Adult Patients with Myasthenia Gravis | |
| 16.12.2020 | Harbour BioMed Completes Its Global Offering and Listing on the Hong Kong Stock Exchange | |
| 25.08.2020 | STAT China: Two more Hong Kong IPO filings, and Beijing’s latest drug price cuts | A version of this digest first appeared in the weekly STAT China newsletter. To receive future editions, sign up here.
Happy Tuesday and welcome back to STAT China. In this edition, two more Hong Kong IPO filings, Beijing’s latest drug pric... |
